Skip to main content
Image coming soon

CAR3 (human) Reporter Assay Kit-3x32 Well

Catalog No.
C08-0339-224
Manufacturer No.
15747-3x32
Manufacturer Name
Cayman Chemical Company
Quantity
1
Unit of Measure
EA
Price: $1,967.11
List Price: $2,185.68

This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide constitutive, high-level expression of human constitutive androstane receptor, isoform 3 (NR1I3), a ligand-dependent transcription factor

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
This nuclear receptor assay system utilizes proprietary non-human mammalian cells engineered to provide constitutive, high-level expression of human constitutive androstane receptor, isoform 3 (NR1I3), a ligand-dependent transcription factor commonly referred to as CAR3. These reporter cells utilize a modified version of human CAR3 in which the native N-terminal DNA binding domain (DBD) has been replaced with that of the GAL4-DBD. The human CAR3 ligand binding domain (LBD) is unaltered and fully functional. The reporter cells also incorporate a luciferase cDNA functionally linked to the GAL4-upstream activation sequence (UAS). Thus, quantifying expressed luciferase activity provides a sensitive surrogate measure of changes in CAR3 activity resulting from direct interaction between a treatment compound and the nuclear receptor. Because this assay system expresses the [GAL4-DBD + hCAR3 LBD] hybrid receptor, the activity of modulators that act through indirect mechanisms (such as those that alter the phosphorylation status of the native N-terminal amino acid sequence of the CARs) may be dampened or go undetected. Contrary to its name, human CAR3 is not constitutively active, rather, it exhibits ligand-dependent activation. The primary application of this reporter assay system is in the screening of test compounds to quantify any functional activity, either agonist or antagonist, that they may exert on human CAR3. Reporter cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryopreservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments. INDIGO Bioscience’s nuclear receptor reporter assays are all-inclusive cell-based assay systems. In addition to CAR3 reporter cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a positive-control agonist, luciferase detection reagent, and a cell culture-ready assay plate.
UPC:
12350000
Condition:
New
Availability:
3 Days
Weight:
1.00 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
15747-3x32


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.